Key Takeaways
- The UK’s revamped innovative licensing and access pathway will see National Health Service partners more “involved in” conversations around the reimbursement of medicines.
- Northern Ireland is set to join the scheme, which at present includes representatives from the devolved health care systems in England, Wales and Scotland in addition to the UK’s drug regulator.
- A priority scheduling pass will also be introduced, which will speed up how quickly companies can access services such as joint advice under the ILAP.
More light has been shed on how the new iteration of the Medicines and Healthcare products Regulatory Agency’s innovative licensing and access pathway (ILAP) will work in practice, including an...
One of the “key improvements” to ILAP is the inclusion of NHS organizations across the UK as “core partners,” Jack Turner, deputy director for commercial medicines access at NHS England,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?